FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3108676144> ?p ?o ?g. }

• W3108676144 endingPage "396" @default.
• W3108676144 startingPage "388" @default.
• W3108676144 abstract "Abstract Context Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide. Objective Explore mechanisms of glucose control by tirzepatide. Design Post hoc analyses of fasting biomarkers and multiple linear regression analysis. Setting Forty-seven sites in 4 countries. Patients or other Participants Three hundred and sixteen subjects with type 2 diabetes. Interventions Tirzepatide (1, 5, 10, 15 mg), dulaglutide (1.5 mg), placebo. Main Outcome Measures Analyze biomarkers of beta-cell function and insulin resistance (IR) and evaluate WL contributions to IR improvements at 26 weeks. Results Homeostatic model assessment (HOMA) 2-B significantly increased with dulaglutide and tirzepatide 5, 10, and 15 mg compared with placebo (P ≤ .02). Proinsulin/insulin and proinsulin/C-peptide ratios significantly decreased with tirzepatide 10 and 15 mg compared with placebo and dulaglutide (P ≤ .007). Tirzepatide 10 and 15 mg significantly decreased fasting insulin (P ≤ .033) and tirzepatide 10 mg significantly decreased HOMA2-IR (P = .004) compared with placebo and dulaglutide. Markers of improved insulin sensitivity (IS) adiponectin, IGFBP-1, and IGFBP-2 significantly increased by 1 or more doses of tirzepatide (P &lt; .05). To determine whether improvements in IR were directly attributable to WL, multiple linear regression analysis with potential confounding variables age, sex, metformin, triglycerides, and glycated hemoglobin A1c was conducted. WL significantly (P ≤ .028) explained only 13% and 21% of improvement in HOMA2-IR with tirzepatide 10 and 15 mg, respectively. Conclusions Tirzepatide improved markers of IS and beta-cell function to a greater extent than dulaglutide. IS effects of tirzepatide were only partly attributable to WL, suggesting dual receptor agonism confers distinct mechanisms of glycemic control." @default.
• W3108676144 created "2020-12-07" @default.
• W3108676144 creator A5003206993 @default.
• W3108676144 creator A5013110210 @default.
• W3108676144 creator A5024563374 @default.
• W3108676144 creator A5040811419 @default.
• W3108676144 creator A5058864022 @default.
• W3108676144 creator A5061113397 @default.
• W3108676144 creator A5072130761 @default.
• W3108676144 creator A5081732583 @default.
• W3108676144 creator A5091446537 @default.
• W3108676144 date "2020-11-24" @default.
• W3108676144 modified "2023-10-16" @default.
• W3108676144 title "Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes" @default.
• W3108676144 cites W1583083185 @default.
• W3108676144 cites W1924955228 @default.
• W3108676144 cites W1965469192 @default.
• W3108676144 cites W1970142642 @default.
• W3108676144 cites W1985712706 @default.
• W3108676144 cites W2007060126 @default.
• W3108676144 cites W2018167495 @default.
• W3108676144 cites W2024751668 @default.
• W3108676144 cites W2025682280 @default.
• W3108676144 cites W2031414916 @default.
• W3108676144 cites W2040319473 @default.
• W3108676144 cites W2043209055 @default.
• W3108676144 cites W2058815839 @default.
• W3108676144 cites W2063188032 @default.
• W3108676144 cites W2072686461 @default.
• W3108676144 cites W2074175997 @default.
• W3108676144 cites W2096846676 @default.
• W3108676144 cites W2121982863 @default.
• W3108676144 cites W2127984332 @default.
• W3108676144 cites W2140997600 @default.
• W3108676144 cites W2142635246 @default.
• W3108676144 cites W2149248906 @default.
• W3108676144 cites W2149717292 @default.
• W3108676144 cites W2152234200 @default.
• W3108676144 cites W2163684433 @default.
• W3108676144 cites W2171137184 @default.
• W3108676144 cites W2192825131 @default.
• W3108676144 cites W2283187206 @default.
• W3108676144 cites W2361659253 @default.
• W3108676144 cites W2550969645 @default.
• W3108676144 cites W2736294384 @default.
• W3108676144 cites W2736390409 @default.
• W3108676144 cites W2742363004 @default.
• W3108676144 cites W2802037482 @default.
• W3108676144 cites W2895135221 @default.
• W3108676144 cites W2895666357 @default.
• W3108676144 cites W2899982133 @default.
• W3108676144 cites W2929875152 @default.
• W3108676144 cites W2954515511 @default.
• W3108676144 cites W2961575013 @default.
• W3108676144 cites W2999928506 @default.
• W3108676144 cites W3004172664 @default.
• W3108676144 cites W3015345942 @default.
• W3108676144 cites W332185995 @default.
• W3108676144 doi "https://doi.org/10.1210/clinem/dgaa863" @default.
• W3108676144 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7823251" @default.
• W3108676144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33236115" @default.
• W3108676144 hasPublicationYear "2020" @default.
• W3108676144 type Work @default.
• W3108676144 sameAs 3108676144 @default.
• W3108676144 citedByCount "99" @default.
• W3108676144 countsByYear W31086761442020 @default.
• W3108676144 countsByYear W31086761442021 @default.
• W3108676144 countsByYear W31086761442022 @default.
• W3108676144 countsByYear W31086761442023 @default.
• W3108676144 crossrefType "journal-article" @default.
• W3108676144 hasAuthorship W3108676144A5003206993 @default.
• W3108676144 hasAuthorship W3108676144A5013110210 @default.
• W3108676144 hasAuthorship W3108676144A5024563374 @default.
• W3108676144 hasAuthorship W3108676144A5040811419 @default.
• W3108676144 hasAuthorship W3108676144A5058864022 @default.
• W3108676144 hasAuthorship W3108676144A5061113397 @default.
• W3108676144 hasAuthorship W3108676144A5072130761 @default.
• W3108676144 hasAuthorship W3108676144A5081732583 @default.
• W3108676144 hasAuthorship W3108676144A5091446537 @default.
• W3108676144 hasBestOaLocation W31086761441 @default.
• W3108676144 hasConcept C126322002 @default.
• W3108676144 hasConcept C134018914 @default.
• W3108676144 hasConcept C142724271 @default.
• W3108676144 hasConcept C151730666 @default.
• W3108676144 hasConcept C170493617 @default.
• W3108676144 hasConcept C185280430 @default.
• W3108676144 hasConcept C204787440 @default.
• W3108676144 hasConcept C27081682 @default.
• W3108676144 hasConcept C2777180221 @default.
• W3108676144 hasConcept C2777391703 @default.
• W3108676144 hasConcept C2777538456 @default.
• W3108676144 hasConcept C2778535154 @default.
• W3108676144 hasConcept C2778938600 @default.
• W3108676144 hasConcept C2779306644 @default.
• W3108676144 hasConcept C2779343474 @default.
• W3108676144 hasConcept C2779829264 @default.
• W3108676144 hasConcept C2780323712 @default.
• W3108676144 hasConcept C2780533449 @default.

• next